Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers
- 943 Downloads
Lysosomal storage diseases (LSDs), lysosomal enzyme deficiencies causing multi-system organ damage, have come to the forefront in newborn screening (NBS) initiatives due to new screening technologies and emerging treatments. We developed a qualitative discussion tool to explore opinions of genetic healthcare providers (HCPs) regarding population-based NBS for MPS types 1 and 2, Pompe, Gaucher, Fabry, and Krabbe diseases. Thirty-eight telephone interviews conducted by a single researcher were analyzed and coded for thematic trends. Six major themes emerged: 1) treatment availability and efficacy is crucial; 2) early age of disease onset is important; 3) ambiguity regarding prognosis is undesirable; 4) parents’ ability to make reproductive decisions is seen by some as a benefit of NBS; 5) paucity of resources for follow-up exists; and 6) the decision-making process for adding conditions to mandated NBS is concerning to HCPs. Among the LSDs discussed, Pompe was considered most appropriate, and Krabbe least appropriate, for NBS. MPS1 and MPS2 were overall considered favorably for screening, but MPS1 ranked higher, due to a perception of better efficacy of therapeutic options. Fabry and Gaucher diseases were viewed less favorably due to later age of onset. The themes identified in this study must be addressed by decision-makers in expanding NBS for LSDs and may be applied to many diseases being considered for NBS in the future.
KeywordsNewborn screening Lysosomal storage diseases Qualitative research Healthcare providers’ opinions
Hematopoetic stem cell transplant
The authors would like to thank Aaron Goldenberg, Ph.D. and the Center for Genetics Research Ethics And Law (CGREAL) at Case Western Reserve University for their advice on study design, use of the ATLAS.ti 6.0 software, and critical reading of the manuscript. We also acknowledge Shire and Pfizer for unrestricted funding that made this study possible.
Conflict of interest
Emily C. Lisi and Shawn E. McCandless declare that they have no conflict of interest.
Human Studies and Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.
No animal studies were carried out by the authors for this article.
- Boelens, J. J., Prasad, V. K., Tolar, J., Wynn, R. F., & Peters, C. (2010). Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatric Clinics of North America, 57(1), 123–145. doi: https://doi.org/10.1016/j.pcl.2009.11.004.PubMedCrossRefGoogle Scholar
- Bombard, Y., Miller, F. A., Hayeems, R., Avard, D., & Knoppers, B. M. (2010). Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. European Journal of Human Genetics, 18(7), 751–760.PubMedPubMedCentralCrossRefGoogle Scholar
- Civallero, G., Michelin, K., de Mari, J., Viapiana, M., Burin, M., Coelho, J., & Giugliani, R. (2006). Twelve different enzyme assays on dried-blood filter paper sample for detection of patients with selected inherited lysosomal storage diseases. Clinica Chimica Acta, 372, 98–102.CrossRefGoogle Scholar
- de Ru, M., Bouwman, M., Wijburg, F., & van Zwieten, M. (2012). Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPSI) diagnoses and its relevance to the ethical debate on newborn screening. Molecular Genetics and Metabolism, 107(3), 501–507.PubMedCrossRefGoogle Scholar
- Duffner, P. K., Caggana, M., Orsini, J. J., Wenger, D. A., Patterson, M. C., Crosley, C. J., … Wasserstein, M. P. (2009). Newborn screening for Krabbe disease: the New York State model. Pediatric Neurology, 40(4), 245–252; discussion 253–245. doi:10.1016/j.pediatrneurol.2008.11.010PubMedCrossRefGoogle Scholar
- Giugliani, R., Federhen, A., Rojas, M. V., Vieira, T., Artigalas, O., Pinto, L. L., … Martins, A. M. (2010). Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genetics and Molecular Biology, 33(4), 589–604. doi:10.1590/S1415-47572010005000093PubMedPubMedCentralCrossRefGoogle Scholar
- Hennink, M., Hutter, I., & Bailey, A. (2011). Qualitative research methods. London: SAGE Publications, Ltd.Google Scholar
- Hoefsloot, L. H., van der Ploeg, A. T., Kroos, M. A., Hoogeveen-Westerveld, M., Oostra, B. A., & Reuser, A. J. (1990). Adult and infantile glycogenosis type II in one family, explained by allelic diversity. American Journal of Medical Genetics, 46, 45–52.Google Scholar
- Kishnani, P. S., Corzo, D., M., N., Byrne, B., Mandel, H., Hwu, W. L., … Wraith, J. E. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology, 68(2), 99–109.Google Scholar
- McClaren, B., Aitken, M., Massie, J., Amor, D., Ukoumunne, O., & Metcalfe, S. (2013). Cascade carrier testing after a child is diagnosed with cystic fibrosis through newborn screening: investigating why most relatives do not have testing. Genetics in Medicine, 15(7), 533–540.PubMedCrossRefGoogle Scholar
- Peters, C., Balthazor, M., & Shapiro, E. G. (1996). Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood, 87, 4864–4902.Google Scholar
- Ross, L. F., & Acharya, K. (2009). Fragile X screening: views of genetic health professionals. American Journal of Medical Genetics. Part A, 15(4), 626–632.Google Scholar
- van El, C. G., Rigter, T., Reuser, A. J., Van der Ploeg, A., Weinreich, S. S., & Cornel, M. C. (2014). Newborn screening for Pompe disease? A qualitative study exploring professional views. BMC Pediatrics, 14(203). doi: https://doi.org/10.1186/1471-2431-14-203.
- Warnock, D. G., Ortiz, A., Mauer, M., Linthorst, G. E., Oliveira, J. P., Serra, A. L., … Wanner, C. (2012). Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrology Dialysis Transplantation, 27(3), 1042–1049.PubMedCentralCrossRefGoogle Scholar
- Weinreich, S. S., Rigter, T., van El, C. G., Dondorp, W. J., Kostense, P. J., Van der Ploeg, A., … Hagemans, M. L. C. (2012). Public support for neonatal screening for Pompe disease, a broad-phenotype condition. Orphanet Journal of Rare Diseases, 7(15). doi: https://doi.org/10.1186/1750-1172-7-15.PubMedPubMedCentralCrossRefGoogle Scholar
- Wraith, J. E., Scarpa, M., Beck, M., Bodamer, O. A., De Meirleir, L., Guffon, N., … Zeman, J. (2008). Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics , 167(3), 267–277.PubMedPubMedCentralCrossRefGoogle Scholar
- Yang, C.-F., Liu, H.-C., Hsu, T.-R., Tsai, F.-C., Chiang, S.-F., Chiang, C.-C., … Niu, D.-M. (2013). A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. American Journal of Medical Genetics Part A , 164A, 54–61.CrossRefGoogle Scholar